DE60042702D1 - Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene - Google Patents

Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene

Info

Publication number
DE60042702D1
DE60042702D1 DE60042702T DE60042702T DE60042702D1 DE 60042702 D1 DE60042702 D1 DE 60042702D1 DE 60042702 T DE60042702 T DE 60042702T DE 60042702 T DE60042702 T DE 60042702T DE 60042702 D1 DE60042702 D1 DE 60042702D1
Authority
DE
Germany
Prior art keywords
siv
gag
pol
hiv
muted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042702T
Other languages
English (en)
Inventor
George N Pavlakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60042702D1 publication Critical patent/DE60042702D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE60042702T 1999-12-23 2000-12-22 Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene Expired - Lifetime DE60042702D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17303699P 1999-12-23 1999-12-23
PCT/US2000/034985 WO2001046408A2 (en) 1999-12-23 2000-12-22 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes

Publications (1)

Publication Number Publication Date
DE60042702D1 true DE60042702D1 (de) 2009-09-17

Family

ID=22630264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042702T Expired - Lifetime DE60042702D1 (de) 1999-12-23 2000-12-22 Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene

Country Status (8)

Country Link
EP (2) EP2128256B1 (de)
JP (1) JP4627950B2 (de)
AT (1) ATE438714T1 (de)
AU (1) AU785133B2 (de)
CA (1) CA2395269C (de)
DE (1) DE60042702D1 (de)
ES (2) ES2329648T3 (de)
WO (1) WO2001046408A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003095605A2 (en) * 2002-05-08 2003-11-20 Pharmacia Italia Spa A chimeric reverse transcriptase and methods for identifying telomerase inhibitors
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB201501523D0 (en) * 2015-01-30 2015-03-18 Univ Plymouth Differential immune response modulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
DE69938044T2 (de) * 1998-05-22 2009-01-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neue post-transkriptionelle regulationselemente und deren verwendung
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
IL146090A0 (en) * 1999-04-26 2002-07-25 Leuven K U Res & Dev A synthetic gene for expression of a retroviral protein with wild type activity in eukaryotic cells

Also Published As

Publication number Publication date
ATE438714T1 (de) 2009-08-15
CA2395269C (en) 2015-12-08
CA2395269A1 (en) 2001-06-28
ES2420842T3 (es) 2013-08-27
WO2001046408A3 (en) 2001-12-13
AU2592301A (en) 2001-07-03
EP2128256A3 (de) 2009-12-23
JP4627950B2 (ja) 2011-02-09
ES2329648T3 (es) 2009-11-30
EP1246913A2 (de) 2002-10-09
EP2128256B1 (de) 2013-06-26
EP1246913B1 (de) 2009-08-05
JP2003517839A (ja) 2003-06-03
WO2001046408A9 (en) 2002-11-07
WO2001046408A2 (en) 2001-06-28
EP2128256A2 (de) 2009-12-02
AU785133B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
HUP0402259A2 (hu) Vakcinák
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
DE122011100037I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie.
DE69941820D1 (en) Rekombinante newcastle-disease-virus rna expressionssysteme und impfstoffe
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
GR20010300012T1 (en) Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of hiv-1
DK0679187T4 (da) Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
EP1402019A4 (de) Molekulare klone mit mutierten hiv-gag/pol-, siv-gag- und siv-env-genen
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
JP2015116196A (ja) レンチウイルスベースの免疫原性ベクター
DE60042702D1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
JP2005531513A5 (de)
ATE285239T1 (de) Dna enthaltende impfstoffen
CN106399376A (zh) 一种整合缺陷型慢病毒载体、其制备方法及应用
WO2007137591A8 (en) Hiv vaccine
AU2002223402A1 (en) A novel gene therapy agent for haemophilia b and its preparation method
WO2004039945A3 (en) Preventive and therapeutic aids vaccines
DE60217958D1 (de) Pseudotypierung von hiv vektoren mit mokola virenhüllen
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2002003917A3 (en) Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
WO2004101801A3 (en) Improved method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding generic tools, as well as the applications of these non-pathogenic amplicons vectors
Hocum et al. 533. A Clinically Relevant Approach for Retargeting Foamy Viral Vectors Into Heterochromatin
Zanotto et al. Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA/fowlpox priming and virus-like particle boosting
Chiu et al. Exchange of genetic sequences of long terminal repeat and the env gene by a promiscuous primate type D retrovirus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition